| Name | Title | Contact Details |
|---|---|---|
Christopher Frankenfield |
Chief Financial Officer | Profile |
Erika Nicol |
Vice President, Head of Human Resources | Profile |
Timothy Hunt |
Chief Culture and Corporate Affairs Officer | Profile |
Salvatore Giovine |
Chief Fnancial Officer | Profile |
Rene Russo |
Chief Executive Officer | Profile |
ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA`s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted prevention treatment for AF. ARCA is also developing rNAPc2 as potential treatment for RNA-associated diseases, initially focused on COVID-19.
CORRECT PHARMACY is a Baltimore, MD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Genyous Life Sciences is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
PowerMedica is a Deerfield Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.